Neurinnov

Key People

• Serge Renaux - Co-Founder, President, and Chief Executive Officer
• David Andreu, Ph.D. - Co-Founder, Chief Technology Officer, Managing Director, and General Manager
• David Guiraud, Ph.D. - Co-Founder and Chief Scientific Officer
• Nicolas Serandour - President and Mandataire Social

Assessment

Team

Aspect: First-time 10+ yrs
Summary: The founding team comprises individuals with over a decade of experience in neurostimulation and related fields.

The co-founders have significant backgrounds in electrophysiology, functional physiology, and microelectronics, contributing to the development of their innovative neurostimulation solutions.

Clinical Need

Aspect: Very Strong
Summary: Neurinnov addresses a critical unmet need for patients with complete tetraplegia.

With over 650,000 individuals affected by tetraplegia in the USA and Europe, and no existing treatments for severe spinal cord injuries, Neurinnov's solution has the potential to significantly improve quality of life.

Competition

Aspect: First mover
Summary: Neurinnov is pioneering selective neurostimulation for hand function restoration.

By enabling selective activation of specific muscles through targeted nerve stimulation, Neurinnov offers a novel solution not currently available in the market.

Technical Challenge

Aspect: Very Complex
Summary: Developing implantable devices for selective neurostimulation involves significant technical challenges.

Achieving precise muscle activation through nerve stimulation requires advanced technology and rigorous testing to ensure safety and efficacy.

Patent

Aspect: Very Strong
Summary: Neurinnov has a robust intellectual property portfolio with multiple patents.

The company's patents cover key aspects of their neurostimulation technology, protecting their innovations and market position.

Financing

Aspect: Medium
Summary: Neurinnov has secured funding from various investors and grants.

The company has raised approximately $5.88 million, including a recent grant, but further investment may be required to support commercialization efforts.

Regulatory

Aspect: Running FIH
Summary: Neurinnov is conducting early-stage feasibility studies.

Successful early-stage studies, including those published in Nature Scientific Reports, demonstrate the potential efficacy of the technology and pave the way for further regulatory approvals.

Opportunity Rollup

Odds of Success

3.95

Peak Market Share

5.65

Segment CAGR

4.9%

Market Segment

Neurology Devices

Market Sub Segment

Neurostimulation Devices

Key Takeaway

Neurinnov's innovative neurostimulation technology addresses a significant unmet need in tetraplegia treatment, positioning the company as a pioneer in the field with strong growth potential.